Urine circulating-tumor DNA (ctDNA) detection of acquired EGFR T790M mutation in non-small-cell lung cancer: An outcomes and total cost-of-care analysis

Lung Cancer

Volumn 110, Issue , 2017, Pages 19-25

  Sands, Jacob ^a   Li, Qianyi ^b   Hornberger, John ^b,c  

^a LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

^b Cedar Associates LLC   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Biopsy; ctDNA; Non small cell lung cancer; Precision medicine; T790M; Urine

Indexed keywords

DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; CIRCULATING TUMOR DNA; TUMOR MARKER;

ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); EPIDERMAL GROWTH FACTOR RECEPTOR GENE; GENE MUTATION; HEALTH CARE COST; HUMAN; LUNG ADENOCARCINOMA; MEDICARE; NON SMALL CELL LUNG CANCER; ONCOGENE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SENSITIVITY ANALYSIS; TUMOR BIOPSY; URINALYSIS; ADULT; ALLELE; AMINO ACID SUBSTITUTION; COST; ECONOMICS; FEMALE; GENETICS; LIQUID BIOPSY; LUNG TUMOR; MALE; MORTALITY; MUTATION; OUTCOME ASSESSMENT; PROCEDURES; PROGNOSIS;

ADULT; ALLELES; AMINO ACID SUBSTITUTION; BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; CIRCULATING TUMOR DNA; COSTS AND COST ANALYSIS; DNA, NEOPLASM; FEMALE; HUMANS; LIQUID BIOPSY; LUNG NEOPLASMS; MALE; MUTATION; OUTCOME ASSESSMENT (HEALTH CARE); PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 85019944753     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2017.05.014     Document Type: Article

References (42)

1. Cancer Statistics Working Group, United States cancer statistics: 1999–2013 incidence and mortality web-based report. Lung Cancer Stat., 2016 (Accessed December 7, 2016) https://www.cdc.gov/cancer/lung/statistics/.
2. Rahib, L., Smith, B.D., Aizenberg, R., Rosenzweig, A.B., Fleshman, J.M., Matrisian, L.M., Siegel, R., Ma, J., Zou, Z., Jemal, A., Smith, B., Smith, G., Hurria, A., Hortobagyi, G., Buchholz, T., Jemal, A., Simard, E., Dorell, C., Noone, A., Markowitz, L., Kohler, B., Edwards, B., Noone, A., Mariotto, A., Simard, E., Boscoe, F., Henley, S., Matrisian, L., Aizenberg, R., Rosenzweig, A., Zauber, A., Lansdorp-Vogelaar, I., Knudsen, A., Wilschut, J., van Ballegooijen, M., Kuntz, K., Mandel, J., Church, T., Bond, J., Ederer, F., Geisser, M., Mongin, S., Edwards, B., Ward, E., Kohler, B., Eheman, C., Zauber, A., Anderson, R., Davies, L., Welch, H., Heller, K., Welch, H., Black, W., Bosch, F., Ribes, J., Diaz, M., Cleries, R., Bruix, J., Sherman, M., Spanknebel, K., Conlon, K., Von Hoff, D., Ervin, T., Arena, F., Chiorean, E., Infante, J., Moore, M., Ma, J., Siegel, R., Jemal, A., Srivastava, S., Gray, J., Reid, B., Grad, O., Greenwood, A., Hawk, E., Kaitin, K., Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 74 (2014), 2913–2921, 10.1158/0008-5472.CAN-14-0155.
3. Cancer Trends Progress Report—2011/2012 Update, National Cancer Institute, NIH, DHHS, Bethesda, MD, April 2010, http://progressreport.cancer.gov. (Accessed May 18, 2017).
4. American Lung Association, Financial burden of cancer care. Cancer Trends Prog. Rep., 2015 (Accessed September 8, 2016) http://progressreport.cancer.gov/after/economic_burden.
5. Mariotto, A.B., Yabroff, K.R., Shao, Y., Feuer, E.J., Brown, M.L., Projections of the cost of cancer care in the United States: 2010–2020. J. Natl. Cancer Inst. 103 (2011), 117–128, 10.1093/jnci/djq495.
6. American Cancer Society Inc., About Non-Small Cell Lung Cancer. https://www.cancer.org/content/dam/CRC/PDF/Public/8703.00.pdf. (Accessed May 18, 2017).
7. Wagner, H., Non–Small cell lung cancer. Clin. Radiat. Oncol., 2012, 805–838, 10.1016/B978-1-4377-1637-5.00042-0 Elsevier.
8. L.V. Sequist, J.W. Neal, Personalized, genotype-directed therapy for advanced non-small cell lung cancer. In: UpToDate, UpToDate. (2016). http://www.uptodate.com/contents/personalized-genotype-directed-therapy-for-advanced-non-small-cell-lung-cancer (Accessed January 11, 2016).
9. Oxnard, G.R., Arcila, M.E., Sima, C.S., Riely, G.J., Chmielecki, J., Kris, M.G., Pao, W., Ladanyi, M., Miller, V.A., Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clin. Cancer Res. 17 (2011), 1616–1622, 10.1158/1078-0432. CCR-10-2692.
10. Yu, H.A., Arcila, M.E., Rekhtman, N., Sima, C.S., Zakowski, M.F., Pao, W., Kris, M.G., Miller, V.A., Ladanyi, M., Riely, G.J., Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin. Cancer Res. 19 (2013), 2240–2247, 10.1158/1078-0432.CCR-12-2246.
11. National Comprehensive Cancer Network, Non-Small Cell Lung Cancer (Version 4.2016), (2016). 10.1016/B978-1-4377-1637-5.00042-0.
12. Jänne, P.A., Yang, J.C.-H., Kim, D.-W., Planchard, D., Ohe, Y., Ramalingam, S.S., Ahn, M.-J., Kim, S.-W., Su, W.-C., Horn, L., Haggstrom, D., Felip, E., Kim, J.-H., Frewer, P., Cantarini, M., Brown, K.H., a Dickinson, P., Ghiorghiu, S., Ranson, M., AZD9291 in EGFR inhibitor-Resistant non-small-cell lung cancer. N. Engl. J. Med. 372 (2015), 1689–1699, 10.1056/NEJMoa1411817.
13. Oxnard, G.R., Thress, K.S., Alden, R.S., Lawrance, R., Paweletz, C.P., Cantarini, M., Yang, J.C.-H., Barrett, J.C., Janne, P.A., Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non-small-cell lung cancer. J. Clin. Oncol. 34 (2016), 3375–3382, 10.1200/JCO.2016.66.7162.
14. Accordino, M.K., Wright, J.D., Buono, D., Neugut, A.I., Hershman, D.L., Trends in use and safety of image-guided transthoracic needle biopsies in patients with cancer. J. Oncol. Pract. 11 (2015), e351–e359, 10.1200/JOP.2014.001891.
15. Wakelee, H., Gadgeel, S., Goldman, J., Reckamp, K., Epidermal growth factor receptor (EGFR) genotyping of matched urine, plasma and tumor tissue from non-small cell lung cancer (NSCLC) patients (pts) treated with rociletinib. J. Clin. Oncol., 34(Suppl), 2016 abstr 9001. https://scholar.google.com/scholar?hl=en&q=Epidermal+growth+factor+receptor+genotyping+of+matched+urine%2C+plasma+and+tumor+tissue+from+non-small+cell+lung+cancer+patients+treated+with+rociletinib&btnG=&as_sdt=1%2C5&as_sdtp=(accessed March 16, 2017).
16. Husereau, D., Drummond, M., Petrou, S., Carswell, C., Moher, D., Greenberg, D., Augustovski, F., Briggs, A.H., Mauskopf, J., Loder, E., Consolidated health economic evaluation reporting standards (CHEERS) statement. Eur. J. Heal. Econ. 14 (2013), 367–372, 10.1007/s10198-013-0471-6.
17. Walton, M.K., Powers, J.H., Hobart, J., Patrick, D., Marquis, P., Vamvakas, S., Isaac, M., Molsen, E., Cano, S., Burke, L.B., Clinical outcome assessments: conceptual foundation—Report of the ISPOR clinical outcomes assessment –emerging good practices for outcomes research task force. Value Heal. 18 (2015), 741–752, 10.1016/j.jval.2015.08.006.
18. Sequist, L.V., Soria, J.-C., Goldman, J.W., Wakelee, H.A., Gadgeel, S.M., Varga, A., Papadimitrakopoulou, V., Solomon, B.J., Oxnard, G.R., Dziadziuszko, R., Aisner, D.L., Doebele, R.C., Galasso, C., Garon, E.B., Heist, R.S., Logan, J., Neal, J.W., Mendenhall, M.A., Nichols, S., Piotrowska, Z., Wozniak, A.J., Raponi, M., Karlovich, C.A., Jaw-Tsai, S., Isaacson, J., Despain, D., Matheny, S.L., Rolfe, L., Allen, A.R., Camidge, D.R., Rociletinib in EGFR-mutated non-small-cell lung cancer. N. Engl. J. Med. 372 (2015), 1700–1709, 10.1056/NEJMoa1413654.
19. Fujii, T., Barzi, A., Sartore-Bianchi, A., Cassingena, A., Siravegna, G., Karp, D., Piha-Paul, S., Subbiah, V., Tsimberidou, A.M., Huang, H., Veronese, S., Di Nicolantonio, F., Pingle, S.C., Vibat, C.R.T., Hancock, S., Berz, D., Melnikova, V.O., Erlander, M.G., Luthra, R., Kopetz, S., Meric-Bernstam, F., Siena, S., Lenz, H.-J., Bardelli, A., Janku, F., Mutation-enrichment next-generation sequencing for quantitative detection of KRAS mutations in urine cell-free DNA from patients with advanced cancers. Clin. Cancer Res., 2592, 2017, 10.1158/1078-0432.ccr-16-2592.
20. Reckamp, K., Melnikova, V., Karlovich, C., Sequist, L., Camidge, D., Wakelee, H., Perol, M., Oxnard, G., Kosco, K., Croucher, P., Samuelsz, E., A highly sensitive and quantitative test platform for detection of NSCLC EGFR mutations in urine and plasma. J. Thorac. Oncol. 11 (2016), 1690–1700, 10.1016/j.jtho.2016.05.035.
21. Sequist, L.V., Goldman, J.W., Wakelee, H.A., Camidge, D.R., Yu, H.A., Varga, A., Solomon, B., Oxnard, G.R., Ou, S.-H.I., Papadimitrakopoulou, V., Chao, B.H., Liu, S.V., Reckamp, K.L., Spira, A.I., Piotrowska, D., Despain, C.A., Karlovich, S., Soria, J.-C., Efficacy of rociletinib (CO-1686) in plasma-genotyped T790M-positive non-small cell lung cancer (NSCLC) patients (pts). J. Clin. Oncol., 33, 2015, 8001.
22. Sequist, L.V., Soria, J.-C., Camidge, D.R., Update to rociletinib data with the RECIST confirmed response rate. N. Engl. J. Med., 2016, 10.1056/nejmc1602688.
23. Goldman, J., Soria, J., Wakelee, H., Camidge, D., Gadgeel, S., Yu, H., Reckamp, K., Papadimitrakopoulou, V., Perol, M., Ou, S., Matheny, S., Despain, D., Isaacson, S., Yurasov, J., Rolfe, L., Sequist, L., Updated results from TIGER-X, a phase I/II open label study of rociletinib in patients with advanced, recurrent T 790M-positive non-small cell lung cancer (NSCLC). J. Clin. Oncol., 2016, 34 http://meetinglibrary.asco.org/content/165669-176.
24. International Society for Pharmacoeconomics and Outcomes Research, ISPOR Good Practices for Outcomes Research Index. http://www.ispor.org/research_initiatives/hs_initiatives.asp (Accessed May 17, 2017).
25. Premier Research Services, Premier Perspective Database. 2013.
26. Shinde, R., Cao, X., Kothari, S., Biopsy procedures and molecular testing utilization and related costs in patients with metastatic lung cancer. J. Manag. Care Spec. Pharm. 22 (2016), 1194–1203, 10.18553/jmcp.2016.15404.
27. Wakelee, H., Melnikova, V., Karlovich, C., Gadgeel, S., Reckamp, K., Goldman, J.W., Camidge, D.R., Pérol, M., Ou, S.-H., Liu, S., Yu, H., Socinski, M., Mekhail, T., Solomon, B., Natale, R., Otterson, G., Papadimitrakopoulou, V., Soria, J.-C., Langer, C., Neal, J., Despain, D., Yurasov, S., Litten, J., Raponi, M., Erlander, M., Sequist, L., MA08.01 a highly sensitive next-Generation sequencing platform for detection of NSCLC EGFR T790M mutation in urine and plasma. J. Thorac. Oncol. 12 (2017), S384–S385, 10.1016/j.jtho.2016.11.434.
28. Wiener, R.S., Schwartz, L.M., Woloshin, S., Welch, H.G., Population-based risk for complications after transthoracic needle lung biopsy of a pulmonary nodule: an analysis of discharge records. Ann. Intern. Med., 155, 2011, 137, 10.7326/0003-4819-155-3-201108020-00003.
29. Garon, E.B., Ciuleanu, T.-E., Arrieta, O., Prabhash, K., Syrigos, K.N., Goksel, T., Park, K., Gorbunova, V., Dario Kowalyszyn, R., Pikiel, J., Czyzewicz, G., Orlov, S.V., Lewanski, C.R., Thomas, M., Bidoli, P., Dakhil, S., Gans, S., Kim, J.-H., Grigorescu, A., Karaseva, N., Reck, M., Cappuzzo, F., Alexandris, E., Sashegyi, A., Eli Lilly, F., Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet 384 (2014), 665–673, 10.1016/S0140-6736(14)60845-X.
30. Johnson, B.E., Kabbinavar, F., Fehrenbacher, L., Hainsworth, J., Kasubhai, S., Kressel, B., Lin, C.Y., Marsland, T., Patel, T., Polikoff, J., Rubin, M., White, L., Yang, J.C.H., Bowden, C., Miller, V., ATLAS, Randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer. J. Clin. Oncol. 31 (2013), 3926–3934, 10.1200/JCO.2012.47.3983.
31. Paz-Ares, L., Soulières, D., Melezínek, I., Moecks, J., Keil, L., Mok, T., Rosell, R., Klughammer, B., Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis. J. Cell. Mol. Med. 14 (2010), 51–69, 10.1111/j.1582-4934.2009.00991.x.
32. Lokhandwala, T., Bittoni, M.A., Dann, R.A., D'Souza, A.O., Johnson, M., Nagy, R.J., Lanman, R.B., Merritt, R.E., Carbone, D.P., Costs of diagnostic assessment for lung cancer: a medicare claims analysis. Clin. Lung Cancer 18 (2017), e27–e34, 10.1016/j.cllc.2016.07.006.
33. Lokhandwala, T., Dann, R., Johnson, M., D'Souza, A.O., Costs of the diagnostic workup for lung cancer: a medicare claims analysis. Int. J. Radiat. Oncol. Biol. Phys. 90 (2015), S9–S10, 10.1016/j.ijrobp.2014.08.142.
34. Sabatini, L.M., Mathews, C., Ptak, D., Doshi, S., Tynan, K., Hegde, M.R., Burke, T.L., Bossler, A.D., Genomic sequencing procedure microcosting analysis and health economic cost-impact analysis: a report of the association for molecular pathology. J. Mol. Diagn. 18 (2016), 319–328, 10.1016/j.jmoldx.2015.11.010.
35. Centers for Medicare & Medicaid Services, July 2016 ASP Pricing File 06/29/2016, 2016 J9299, J9271. https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Part-B-Drugs/McrPartBDrugAvgSalesPrice/2016ASPFiles.html (Accessed August 25, 2016).
36. Handorf, E.A., McElligott, S., Vachani, A., Langer, C.J., Bristol Demeter, M., Armstrong, K., Asch, D.A., Cost effectiveness of personalized therapy for first-line treatment of stage IV and recurrent incurable adenocarcinoma of the lung. J. Oncol. Pract. 8 (2012), 267–274, 10.1200/JOP.2011.000502.
37. Petteys, S., Zeman, J., Stahlmann, C., Overdiagnosis in lung cancer screening, cost-effectiveness of computed tomography screening for lung cancer, and decision analysis of need for biopsy-proven diagnosis before stereotactic ablative radiotherapy for lung cancer. Am. J. Respir. Crit. Care Med. 192 (2015), 1009–1011, 10.1164/rccm.201504-0804RR.
38. Paz-Ares, L.G., de Marinis, F., Dediu, M., Thomas, M., Pujol, J.-L.J.L., Bidoli, P., Molinier, O., Sahoo, T.P., Laack, E., Reck, M., Corral, J., Melemed, S., John, W., Chouaki, N., Zimmermann, A.H., Visseren-Grul, C., Gridelli, C., PARAMOUNT, Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J. Clin. Oncol. 31 (2013), 2895–2902, 10.1200/jco.2012.47.1102.
39. Yabroff, K.R., Warren, J.L., Brown, M.L., Costs of cancer care in the USA: a descriptive review. Nat. Clin. Pract. Oncol. 4 (2007), 643–656, 10.1038/ncponc0978.
40. Howlader, N., Noone, A.M., Krapcho, M., Garshell, J., Neyman, N., Altekruse, S.F., Kosary, C.L., Yu, M., Ruhl, J., Tatalovich, Z., Cho, H., Mariotto, A., Lewis, D.R., Chen, H.S., Feuer, E.J., Cronin, K.A., (eds.) SEER Cancer Statistics Review, 1975-2010, 2017, National Cancer Institute, Bethesda, MD based on November 2012 SEER data submission, posted to the SEER web site, April 2013. http://seer.cancer.gov/csr/1975_2010/.
41. Barlesi, F., Scherpereel, A., Rittmeyer, A., Pazzola, A., Ferrer Tur, N., Kim, J.H.J.-H., Ahn, M.J.M.-J., Aerts, J.G.J.V., Gorbunova, V., Vikström, A., Wong, E.K., Perez-Moreno, P., Mitchell, L., Groen, H.J.M., Vikstrom, A., Wong, E.K., Perez-Moreno, P., Mitchell, L., Groen, H.J.M., Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089). J. Clin. Oncol. 31 (2013), 3004–3011, 10.1200/JCO.2012.42.3749.
42. Sabatini, L.M., Mathews, C., Ptak, D., Doshi, S., Tynan, K., Hegde, M.R., Burke, T.L., Bossler, A.D., Genomic sequencing procedure microcosting analysis and health economic cost-impact analysis: a report of the association for molecular pathology. J. Mol. Diagn. 18 (2016), 319–328, 10.1016/j.jmoldx.2015.11.010.